Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADXSNASDAQ:PBLANASDAQ:PHASNASDAQ:VLON Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.55+1.9%$0.69$0.50▼$1.95$5.91M1.6220,557 shs426 shsPBLAPanbela Therapeutics$0.44+7.3%$0.75$0.40▼$477.00$1.43M1.4873,274 shs25,779 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shsN/AVLONVallon Pharmaceuticals$0.43-2.3%$0.67$0.21▼$12.92$5.80M-1.145.78 million shs25,073 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals+1.85%-3.51%-22.54%-8.33%-53.39%PBLAPanbela Therapeutics+7.29%-10.11%-31.25%-89.70%-99.87%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%+25.00%VLONVallon Pharmaceuticals-2.13%-14.24%-43.59%+56.49%-94.61%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APBLAPanbela Therapeutics0.7049 of 5 stars3.50.00.00.00.00.00.6PHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVLONVallon PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals2.00HoldN/AN/APBLAPanbela Therapeutics3.00Buy$500.00113,536.36% UpsidePHASPhaseBio PharmaceuticalsN/AN/AN/AN/AVLONVallon PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest PHAS, VLON, ADXS, and PBLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024PBLAPanbela TherapeuticsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$10K591.25N/AN/A($2.27) per share-0.24PBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/APHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00VLONVallon Pharmaceuticals$100K58.00N/AN/A$0.18 per share2.39Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/A-3,967.23%-339.10%5/21/2024 (Estimated)PBLAPanbela Therapeutics-$25.26M-$669.09N/AN/AN/AN/A-70,194.55%-172.92%5/2/2024 (Estimated)PHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/AVLONVallon Pharmaceuticals-$7.02M-$0.78N/A∞N/AN/A-230.48%-124.89%N/ALatest PHAS, VLON, ADXS, and PBLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023PBLAPanbela Therapeutics-$24.34-$65.90-$41.56-$65.90N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AVLONVallon PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/A0.300.30PBLAPanbela TherapeuticsN/A0.250.25PHASPhaseBio PharmaceuticalsN/A0.470.47VLONVallon PharmaceuticalsN/A2.292.29OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%PBLAPanbela Therapeutics4.37%PHASPhaseBio Pharmaceuticals49.02%VLONVallon Pharmaceuticals8.74%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%PBLAPanbela Therapeutics0.01%PHASPhaseBio Pharmaceuticals9.90%VLONVallon Pharmaceuticals37.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala PharmaceuticalsN/A10.75 million10.68 millionNot OptionablePBLAPanbela Therapeutics63.48 million3.48 millionNot OptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableVLONVallon Pharmaceuticals313.48 million8.45 millionNot OptionablePHAS, VLON, ADXS, and PBLA HeadlinesSourceHeadlineQuestcor Pharmaceuticals,forbes.com - July 21 at 11:15 PMVallon Pharmaceuticals' shareholders approve reverse merger with California companybizjournals.com - April 20 at 11:09 PMVallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Splitfinance.yahoo.com - April 20 at 11:09 PMVallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023finance.yahoo.com - April 12 at 5:20 PMLab Notes: CHOP gets $10M research gift; Vallon seeks greater shareholder support for mergerbizjournals.com - April 7 at 3:29 PMVallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ETfinance.yahoo.com - April 4 at 1:30 PMVallon Pharmaceuticals Inc.: Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Resultsfinanznachrichten.de - February 24 at 6:18 PMVallon Pharmaceuticals Reports Fiscal Year 2022 Financial Resultsfinance.yahoo.com - February 24 at 8:19 AMIs Vallon Pharmaceuticals Inc (VLON) recent surge justifiedbenzinga.com - February 14 at 6:48 PMVallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch Eventfinance.yahoo.com - January 11 at 9:46 AMSHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vallon Pharmaceuticals, Inc. - VLONbenzinga.com - December 27 at 6:38 PMVallon rockets as it announces merger with GRI Biothepharmaletter.com - December 15 at 11:44 AMSay goodbye to Vallon as a low-profile NKT cell startup steps into its battered shoes on Nasdaqendpts.com - December 14 at 12:21 PMVallon Pharmaceuticals to merge with California biotech firm in 'best path forward'bizjournals.com - December 14 at 12:21 PMWhat's Going On With Vallon Pharmaceuticals Stock Today?msn.com - December 14 at 12:21 PMWhy Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarketbenzinga.com - December 14 at 7:15 AMVallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulatorsfinance.yahoo.com - December 13 at 4:19 PMVallon Pharmaceuticals Reports Third Quarter 2022 Financial Resultsfinance.yahoo.com - November 3 at 8:06 PMVallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - July 28 at 12:15 PMVallon Pharmaceuticals, Inc. (VLON)finance.yahoo.com - July 20 at 12:07 AMVallon Pharmaceuticals plans $3.9M stock sale to support exploration of strategic alternativesbizjournals.com - May 16 at 8:29 PMVallon Pharmaceuticals to raise $3.9M in stock offeringseekingalpha.com - May 13 at 4:14 PMVallon Pharmaceuticals Announces $3.9 Million Registered Direct Offeringfinance.yahoo.com - May 13 at 4:14 PMVallon Pharma Posts Additional Data From SEAL Study Of Formulated CNS Stimulantfinance.yahoo.com - May 12 at 3:50 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Global benchmarks mostly climb despite worries about US economyApril 26, 2024 3:21 AMView Stock market today: Global benchmarks mostly climb despite worries about US economyFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? April 9, 2024 6:07 AMView Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? Penny Stock Quantum-Si Incorporated Readies For Lift-OffApril 9, 2024 7:14 AMView Penny Stock Quantum-Si Incorporated Readies For Lift-OffAll Headlines Company DescriptionsAyala PharmaceuticalsNASDAQ:ADXSAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Panbela TherapeuticsNASDAQ:PBLAPanbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.PhaseBio PharmaceuticalsNASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.Vallon PharmaceuticalsNASDAQ:VLONVallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.